The present invention provides a chromone oxime derivative of formula (1), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amine acid glutamate and presents an advantageously high brain exposure upon oral administration, for thetreatment or prevention of levodopa-induced dyskinesia. The present invention aise providesan improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (1) in combination with levodopa.
